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edications can lead to depressive symptoms.
These effects can be direct, by altering levels of neuro-
transmitters in the central nervous system (CNS).
Alternatively, they can be indirect, by causing fatigue,
diminished appetite, sedation, or other side effects, lead-
ing to subsequent frustration, demoralization, or even
a full depressive episode. However, it is often difficult to
ascertain whether a medication has caused depression in
any given patient. Depression is substantially more com-
mon in patients with medical illness than it is in the gen-
eral population. For example, approximately 10% to
20% of patients with acute cardiac disease, diabetes,
renal failure, or cancer suffer from current major depres-
sive disorder (MDD), and even more patients have clin-
ically significant, subsyndromal depressive symptoms.
1-4
Therefore, though depression may appear concurrently
with one or more medications used to treat medical ill-
ness, depression is so common in these patients that this
temporal connection may be coincidental. In addition,
the vast majority of studies that associate medications
with depression have been case reports and case series
(not systematic investigations) and have been limited by
small and potentially biased samples. Furthermore, these
reports typically do not use standardized instruments to
evaluate the presence or severity of the apparent depres-
sion; they instead rely on general reports of symptoms.
Prospective, well-controlled trials examining the links
between a medication and depression are relatively rare,
and may contradict clinical lore that says that a certain
medication causes depression. 
In this article, we will carefully examine the links
between medications and the onset and progression of
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The literature is filled with reports that link medications
with the onset or progression of depression. Because
depression is so common in patients with medical illness,
assessing whether a medication has in fact caused depres-
sion, or whether the relationship is coincidental, can be
challenging. In this article, we review the literature on the
association between medications and depression. For most
agents, there are case reports or small studies linking the
medication with the onset of depression, but more rigor-
ous prospective studies are either lacking or found no
association between the agent and depression. However,
several medications, (eg, barbiturates, vigabatrin, topira-
mate, flunarizine, corticosteroids, mefloquine, efavirenz,
and interferon-) do appear to cause depression in some
patients and should be used with caution in patients at
risk for depression.  
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depression. We have chosen to focus on medications
used to treat common conditions (eg, cardiac illness)
and on those medications reported to cause depression
(eg, isotretinoin [Accutane], corticosteroids). We end
with a summary of our findings and provide clinical
guidance. 
Neurologic medications
Medications for the treatment of seizure disorders
Patients with epilepsy are at significantly increased risk
for MDD (6% to 80% prevalence rates) and depressive
symptoms when compared with healthy adults or to
those with other chronic conditions.
5,6Thoughts of suicide
and suicide attempts have also been associated with the
use of anticonvulsants, and they occur with a higher fre-
quency in patients with epilepsy.
6,7Although a number of
factors (including genetics, the location of seizure activ-
ity, and psychosocial problems) may contribute to
depression, use of anticonvulsant agents may also play
a role.
6
Most anticonvulsants have been linked with the devel-
opment of depressive symptoms in a small percentage of
patients, but three medications (barbiturates, vigabatrin,
and topiramate) are thought to be more of a catalyst than
others.
5,8 These three medications all work on the
γ−aminobutyric acid (GABA) neurotransmitter system
and may produce fatigue, sedation, impaired cognition,
and depressed mood.
5
Phenobarbital, one of the oldest barbiturate anticonvul-
sants, was the first medication to be linked with depres-
sive symptoms.
9,10 In a series of naturalistic studies that
followed children with epilepsy over 2 years, Brent and
associates
9,10 discovered that even after controlling for
stressful life events and family conflict, 40% of pheno-
barbital-treated patients complained of depression, com-
pared with 4% of carbamazepine-treated patients
(P=.02).
10These rates of depression remained stable over
2 years (38% in phenobarbital-treated patients vs 0% in
carbamazepine-treated patients) when phenobarbital
was continued, but it frequently resolved upon its dis-
continuation (P=.05), suggesting a causal role.
9Although
more recent studies of barbiturates have revealed a
depression prevalence rate of approximately 10%,
8
depression continues to present a significant problem for
these patients, and patients taking barbiturates should be
monitored for depression. 
Vigabatrin, an anticonvulsant that works by irreversibly
inhibiting GABA transaminase and thus increasing CNS
GABA levels, has also been associated with depression.
11
A systematic review of double-blind, placebo-controlled
trials of vigabatrin found a 12% incidence of depressive
symptoms in vigabatrin-treated patients, compared with
an incidence of 3.5% in those receiving placebo.
11
Depression associated with vigabatrin therapy can occur
at any time during treatment,
12 but it often occurs shortly
after treatment initiation or a dose increase
13 and is more
likely to occur in those with a history of depression.
12
Topiramate, an anticonvulsant used for treatment of
epilepsy, migraine headaches, smoking cessation, and
weight loss, has been linked to the development of
depression in approximately 10% of patients.
8,14 The
depressive symptoms associated with use of topiramate
appear to be dose-dependent, to be more frequent in
patients with a personal or family history of depression
or other psychiatric illness, and to occur more often after
rapid dose escalation.
14,15 In one study, patients who
underwent rapid escalation had a 5-fold increased risk of
depression development; in patients with a history of
depression, this risk increased by 23-fold.
14Therefore, for
patients at increased risk, a slow dose-titration schedule
and increased monitoring for depressive symptoms is
warranted. Of note, topiramate may be a useful treatment
for depressive symptoms in the context of MDD or bipo-
lar disorder.
16,17
Several anticonvulsants (including tiagabine, zonisamide,
levetiracetam, and felbamate) have been associated in
placebo-controlled trials with depressive symptoms in
approximately 4% to 7% of patients.
8 In general, patients
at high risk for depression who are prescribed barbitu-
rates, vigabatrin, or topiramate should be monitored for
the emergence of depression; a conservative approach to
the dosing and titration of medications is also indicated.
If a patient develops depressive symptoms while on one
of these medications, a switch to a less depressogenic
agent may be appropriate.
Medications for the treatment of Parkinson’s disease
Like patients with epilepsy, patients with Parkinson’s dis-
ease (PD) are at increased risk for depression. Most stud-
ies estimate that 25% to 45% of patients with PD also
suffer from depression
18,19; this is important as depression
is one of the strongest predictors of quality of life in
patients with PD.
20Abnormalities in dopaminergic trans-
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mission have consistently been identified as pathophysi-
ological factors that may contribute to the high preva-
lence of depression in patients with PD
18,19,21; however,
abnormalities in the serotonergic and noradrenergic neu-
rotransmitter systems may also play a role. 
The mainstay of therapy for patients with PD is
dopamine replacement (typically with levodopa, a
dopamine precursor). Levodopa has been suspected of
causing depression in a small percentage of patients;
18
one recent study identified a significant increase in
depression among patients treated with levodopa for 1
year.
22Amantadine, an adjunctive agent that appears to
potentiate dopamine signaling in the brain, has been
associated with depression in a small number of PD
patients.
23 However, it also has been shown to have anti-
depressant properties when used adjunctively with stan-
dard depression treatments in patients with PD.
24
Other dopamine agonists are also used in patients with
new-onset PD due to their improved side-effect profiles.
Fortunately, none of these medications has been associ-
ated with depression; instead, several (eg, pramipexole,
ropinirole) have been noted to have antidepressant prop-
erties.
25,26 Monoamine oxidase inhibitors (MAOIs) and
catechol-o-methyltransferase (COMT) inhibitors (which
increase synaptic dopamine levels) also have not been
associated with depression. In fact, MAOIs have antide-
pressant effects and continue to be used for the treat-
ment of MDD. Selegeline, an MAO-B inhibitor, fre-
quently used in patients with PD, has been found to have
antidepressant effects in this population.
22
In summary, depression in patients with PD is common
and has a significant impact on quality of life; it should be
treated aggressively when it is detected. Fortunately, most
medications used for PD have not been associated with
depression, and several agents may improve depression.
Caution should be taken when using levodopa or aman-
tadine, as these medications appear to increase depres-
sive symptoms most often. 
Medications for the treatment of migraine headaches
Depression and migraine headaches frequently co-occur.
Patients with migraine headaches have a 2- to 4-fold
increased risk for depression,
27 while patients with
depression are at a 3-fold increased risk for developing a
migraine headache.
28This bidirectionality suggests that
these disorders share a common pathophysiology, most
likely involving the serotonergic and GABA-ergic neu-
rotransmitter systems.
29 Depression in these patients not
only impacts quality of life, but may also adversely affect
the overall prognosis of migraine improvement.
30
Serotonin agonists (eg, sumatriptan, nalatriptan) are first-
line agents for the acute treatment of migraine
headaches. To date, these medications have not been
associated with the onset of depression and may decrease
both depressive symptoms and the frequency and inten-
sity of migraine headaches in patients who suffer from
both migraines and MDD.
31 Ergot alkyloids (eg, ergota-
mine, dihydroergotamine), another acute treatment for
migraine headaches, also appear to lack depressogenic
effects.
In contrast, flunarizine, a calcium-channel antagonist
used for acute and prophylactic treatment of migraine
headaches, has been associated with depression. In a ran-
domized, double-blind, prospective study of migraine
prophylaxis, 8% of flunarizine-treated patients developed
depressive symptoms that led to treatment discontinua-
tion.
32 As a result of this medication’s effects on mood
and its propensity to cause extrapyramidal symptoms, it
now is considered as a second-line treatment for patients
with migraines.
32,33
Prophylactic treatment may be accomplished through the
use of anticonvulsants (eg, topiramate, valproic acid), tri-
cyclic antidepressants (TCAs) (eg, amitriptyline), or β-
blockers (eg, propranolol), among others. While valproic
acid does not appear to increase depression risk, topira-
mate does.
8 Depression occurs in approximately 10% of
topiramate-treated patients; the risk of depression
increases significantly in patients with a history of
depression and with rapid dose escalation.
8,14,15
Amitriptyline and other TCAs are effective for treating
depression and may be appropriate for treatment of
comorbid migraine headaches and depression.
30 Finally,
although β-blockers were once thought to cause depres-
sive symptoms,
34-36 recent studies (including a large meta-
analysis) have shown that they do not.
37,38
In sum, there is a strong, bidirectional relationship
between depression and migraine headaches. In patients
with a history of depression or who are currently
depressed, topiramate and flunarizine should be avoided
when possible; if treatment with these medications is
required, depressive symptoms should be monitored. For
these patients, acute treatment with serotonin agonists
and prophylactic treatment with TCAs might be consid-
ered, as such treatment could alleviate symptoms of both
depression and migraine headaches.
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Medications for the treatment of multiple sclerosis
Patients with multiple sclerosis (MS) are at significantly
increased risk for depression; one study found a 2.3-fold
increase in depression risk, even after controlling for age
and gender.
39At present there is no consensus regarding
the pathophysiological link between depression and MS;
while some researchers suggest increased rates of
depression in patients with lesions in specific areas of the
brain (eg, right temporal lobe, superior frontal or pari-
etal regions), others have found no such relationship.
40
In patients with MS, depression has been associated with
worse quality of life,
41 increased levels of disability,
42
worse adherence to MS treatment,
43,44 and an increased
risk of suicide in some studies.
45
Interferon (IFN)-β-1a and IFN-β-1b are two of the most
common disease-modifying agents used to treat MS.
Given the risk of depression using IFN-α in patients
with HCV infection (see Anti-infective agents section),
there has been significant concern that IFN-β similarly
causes depressive symptoms. Although a few early stud-
ies found that IFN-β-1b-treated patients suffered from
high rates of depression and suicidal ideation,
43,46 these
findings have not been replicated. In a secondary analy-
sis of a double-blind, placebo-controlled study evaluat-
ing the efficacy of IFN-β-1a in 365 MS patients, Patten
and associates
47 found no significant differences in
depression between IFN-β-1a and placebo at 36-month
follow-up. Others similarly found no increased risk of
depression with IFN-β treatment in patients with MS
who were re-evaluated at 65 months; they suggested that
pretreatment depression and disability were the biggest
predictors of depression at follow-up.
48
Other agents used in the treatment of MS include 4-
aminopyridine, glatiramer, fingolimod, mitoxantrone, and
natalizumab. Unfortunately, few data exist regarding the
rates of depression in patients taking these medications.
Depression, specifically, has been studied for only two of
these medications: natalizumab and fingolimod. Two ran-
domized controlled trials (RCTs) of natalizumab found
no increased risk of depression.
49,50A randomized trial of
fingolimod similarly found no increase in depression com-
pared with placebo.
51 The incidence of depression in
patients treated with mitoxantrone, glatiramer, and 4-
aminopyridine has not been specifically studied. However,
studies of these medications have found them to be safe
and well-tolerated, suggesting that depression may not be
a significant side effect of these agents. 
Overall, despite the prevalence of depression among
patients with MS, medications do not appear to play a
role in its development, even in those at risk for depres-
sion. Monitoring for depression should be considered for
patients on IFN-β; however, the likelihood that it will
cause depression is low.
Cardiovascular medications
In this section, we will review the links between depres-
sion and a variety of cardiovascular medications; we
refer the reader to published reviews of their other neu-
ropsychiatric complications.
52,53
β-Blockers
A connection between the use of β-adrenergic blockers
and depression has long been hypothesized. The
lipophilic β-blockers (eg, propranolol and metoprolol)
cross the blood-brain barrier much more easily than do
nonlipophilic β-blockers (eg, atenolol); as a result, they
are thought to be associated with higher rates of neu-
ropsychiatric consequences.
The association between the use of β-blockers and
depression remains controversial. Many case reports and
several small reviews have linked use of propranolol
with depression,
34,35 and a trial by Thiessen and col-
leagues
36 found that treatment with propranolol was
associated with higher rates of antidepressant prescrip-
tions than with other β-blockers (both lipophilic and
hydrophilic). In contrast, a RCT of 312 patients who
received propranolol found no association between this
agent and depression at 1 year.
54 Furthermore, several of
the trials listed above did not account for confounding
variables (eg, benzodiazepine use and frequency of out-
patient visits) that were found to account for the appar-
ent relationship between use of β-blockers and the diag-
nosis of depression; in one study there was no
association between use of β-blockers and depression
after accounting for this correction.
55 Finally, a compre-
hensive review of more than 5800 patients prescribed
propranolol found that this agent was rarely associated
with depressive symptoms, and that such symptoms typ-
ically arose after long-term use.
56
When trials have been expanded to include use of other
β-blockers, the majority of studies and reviews found no
association between β-blockers and depression.
37,38 The
most extensive analysis of the association between β-
PAGES_11_AG_1040_BA.qxd:DCNS#48  5/03/11  11:36  Page 112blockers and depression, however, was a meta-analysis
of 15 trials of more than 35 000 patients.
37 Ko and col-
leagues
37 found that β-blockers were not associated with
a significant increase in reports of depressive symptoms;
furthermore, there were no differences between out-
comes following use of lipophilic and nonlipophilic
agents. More recent reviews have confirmed this lack of
an association.
38
Finally, pindolol, because of its effects on 5-HT1A autore-
ceptors, has been actively studied as a potential aug-
menting agent for patients with depression. A meta-
analysis of RCTs of pindolol augmentation of selective
serotonin reuptake inhibitors (SSRIs) found that pin-
dolol appears to speed up the response to SSRIs,
although it does not appear to improve overall response
rates.
57
Angiotensin-converting enzyme inhibitors
In contrast to β-blockers, angiotensin-converting enzyme
(ACE) inhibitors have not been significantly linked with
depression. In fact, while several case reports and a
small, open trial have found these agents efficacious in
the treatment of major depression,
58 larger, randomized
trials have not been performed. There are fewer reports
of mood effects associated with other ACE inhibitors; in
one report, lisinopril was used in the adjunctive treat-
ment of depression.
59The newer angiotensin-II receptor
blockers (ARBs) (eg, losartan, valsartan, and irbesartan)
similarly do not appear to have clear associations with
depression. 
Calcium-channel blockers 
Calcium-channel blockers have relatively low rates of
adverse neuropsychiatric consequences. Calcium-chan-
nel blockers may be associated with fatigue, but they
have not been associated with depression.
52,60Verapamil
has been the most-studied calcium-channel blocker for
mania and bipolar disorder and it has had mixed, but
generally positive, results; this agent may be a viable
option for patients with bipolar disorder who are preg-
nant or who fail first-line therapies. 
Calcium-channel blockers have been studied in the
treatment of depressive symptoms, with only modest
results. Verapamil was less effective than amitriptyline
(a TCA) in a double-blind trial for depression,
61 and inef-
fective for depression among patients refractory to
TCAs.
62 Furthermore, because calcium-channel blockers
may be effective in the treatment of cerebrovascular dis-
ease, nimodipine has been used to augment antidepres-
sant treatment in patients suffering from vascular
depression (ie, new-onset depression in older adults
associated with vascular lesions) in double-blind,
placebo-controlled studies.
63 Both studies found that the
addition of nimodipine was superior to placebo in reduc-
ing depressive symptoms and in lowering rates of recur-
rence. 
Diuretics
Diuretics are generally associated with low rates of neu-
ropsychiatric adverse events. One series of eight patients
reported a link between use of thiazide diuretics and
depression,
64 although further evidence for this associa-
tion is lacking. Other diuretics have relatively few neu-
ropsychiatric effects. Loop diuretics (such as furosemide
and ethacrynic acid) have not been associated with
mood syndromes. Epstein and Grant
65 found that nearly
half of carbonic anhydrase-inhibitor-treated patients had
a mild syndrome of fatigue, malaise, anorexia, and
depression, and that such symptoms were associated
with acidosis. 
Centrally acting antihypertensive agents
Clonidine, a central α-adrenergic agonist, is associated
with a number of neuropsychiatric effects; fatigue and
sedation are the most common effects, with sedation
occurring in one third or more of patients.
53 Rarely,
mood disturbance has been described with clonidine;
pooled information suggests that depression occurs in
approximately 1% to 2% of patients. There are no case
reports of clonidine-induced depression or mania,
though there has been one report of hypomania upon
withdrawal of clonidine.
66
Methyldopa, another centrally acting antihypertensive
medication, is infrequently used in clinical practice (except
in those with pregnancy-induced hypertension). It may
reduce blood pressure via central α-2 agonism, and may
also act as a false (norepinephrine) neurotransmitter.
53As
with many cardiovascular agents, common side effects are
sedation and fatigue; sedation occurs in approximately one
third of methyldopa-treated patients, with high rates of
associated fatigue.
67 However, perhaps the best-known
neuropsychiatric consequence of methyldopa use is
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quently with methyldopa than with most other antihyper-
tensive agents, and it is thought that this effect may be
related to reduced norepinephrine levels. An early study
of methyldopa found increased rates of depression, espe-
cially in those with a history of depression,
68 and a study of
elderly patients found methyldopa to be more strongly
associated with depressive symptoms than were β-block-
ers
69; overall, it appears that reported depressive reactions
to methyldopa often occur in those with prior depressive
episodes.
70 In contrast, a review of the literature by Long
and Kathol
71 found no clear evidence that methyldopa (in
contrast to reserpine) was associated with depressive
symptoms. Similarly, a review of 80 patients found no sig-
nificant association between methyldopa and depression.
72
Reserpine
Reserpine, an older antihypertensive medication that is
now rarely used, can have a variety of neuropsychiatric
effects. This agent acts by inhibiting the sequestration of
monoamine neurotransmitters into storage granules,
resulting in the metabolism of these neurotransmitters
by monoamine oxidase (MAO). This depletion of cate-
cholamine neurotransmitters results in its antihyperten-
sive effects and likely contributes to its association with
depression.
53
Reserpine has long been associated with depressive symp-
toms with a number of reports in the 1950s that linked
reserpine use with depression,
73 and a later review citing
an incidence of up to 15%.
74 However, other (generally
more recent) reports call this association into question.
First, the depressive symptoms associated with use of
reserpine appear to include sedation, malaise, and
fatigue.
53,75 Patients with these symptoms alone may not
meet formal criteria for major depression but instead
exhibit subsyndromal depression.
53,75Those who do meet
full criteria tend to receive higher doses and to have a his-
tory of depression. Furthermore, two relatively large stud-
ies (one with over 4000 patients examining the onset of
depressive symptoms among patients taking diuretics, β-
blockers, and reserpine,
76 and the other of elderly individ-
uals with hypertension who used low doses of reserpine),
77
found very low rates of depression with reserpine use. In
summary, reserpine is associated with fatigue and sedation
in a substantial subset of patients, and may be associated
with depressive symptoms, although this latter association
is neither as strong nor as clear as was once thought.
α-Adrenergic agents 
The α1-adrenergic antagonists (eg, prazosin, doxazosin,
and alfuzosin) are used as antihypertensive agents and
to treat symptoms of benign prostatic hypertrophy. In
general, there are few adverse neuropsychiatric conse-
quences associated with these medications. Depression
has not been consistently associated with this class of
agents, although there have been rare reports associated
with prazosin use. Prazosin has been increasingly stud-
ied in the treatment of post-traumatic stress disorder
(PTSD). 
Vasodilators
Hydralazine, a systemic vasodilator whose use is usually
reserved for patients with severe hypertension, on occa-
sion has been linked with neuropsychiatric side effects.
Rarely, hydralazine has been associated with the onset
of depression
52; overall it is not linked to mood distur-
bance. Nitrates (eg, nitroglycerin, isosorbide dinitrate,
and nitroprusside), most commonly used to treat angina,
have minimal neuropsychiatric side effects. However, a
single case report has described hallucinations and sui-
cidal ideation in a patient taking isosorbide dinitrate.
78
Antiplatelet and anticoagulant agents
Aspirin (salicylic acid) has few neuropsychiatric conse-
quences. The anti-inflammatory effects of aspirin have
been postulated to have potential benefit in depression,
given recent suggestions that inflammation may con-
tribute to the pathophysiology of this disease. The
antiplatelet agent clopidogrel has not been associated
with significant neuropsychiatric consequences. Similarly,
the anticoagulant medications, heparin and warfarin, are
not commonly associated with neuropsychiatric effects,
nor are enoxaparin or the glycoprotein IIb/IIIa
inhibitors.
Selected antiarrhythmic medications
Amiodarone
Thyroid abnormalities—including hypothyroidism and
hyperthyroidism—occur in approximately 15% of
patients taking amiodarone due to its high iodine con-
tent and its direct toxic effects on the thyroid.
79Through
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this indirect mechanism, neuropsychiatric effects of
amiodarone may occur, as hypothyroidism may cause
fatigue and depressive symptoms,
80 and hyperthyroidism
can (more rarely) be associated with depressive symp-
toms.
81Amiodarone has also, on occasion, been directly
linked with depressive symptoms.
82,83
Digoxin
Digoxin has been associated with a wide variety of neu-
ropsychiatric side effects, at both toxic and therapeutic
levels (see Keller and Fishman’s excellent review).
53
Although such effects include depression (the prescrib-
ing information for digoxin reports “mental disturbance”
in 5% of patients taking digoxin as opposed to 1% with
placebo), delirium and psychosis are far more common
with this agent.
84 Depressive symptoms have been asso-
ciated with digoxin in small trials and case reports, and
digoxin toxicity can masquerade as depression.
85
Depression linked with use of digoxin presents with
prominent fatigue, low appetite, and impaired sleep.
Despite these reports, however, larger prospective trials
have not supported a strong link between use of digoxin
and depression.
86,87
Lipid-lowering agents 
The HMG-CoA reductase inhibitors (“statins”), the
most commonly used lipid-lowering agents, have been
associated with few neuropsychiatric effects.
88 Lovastatin
and pravastatin are more lipophilic than are other agents
(eg, atorvastatin and pravastatin); however, clinical expe-
rience has not found great differences between these
agents.
Low cholesterol levels have been correlated with depres-
sion and suicide in several longitudinal studies, with one
study noting a 4- to 7-fold increase in risk of severe
depressive symptoms in men with chronically low cho-
lesterol levels.
89 Despite these findings, lowering serum
cholesterol with statins has not been associated with
increased rates of depression, noncardiac deaths, or sui-
cide in several large prospective studies.
90,91 Overall, there
have been only a handful of reports of depressive symp-
toms associated with statin use,
92 and prospective studies
and reviews of statins’ effects on mood have found that
these agents do not consistently cause depression.
88,93
The lipid-lowering agents gemfibrozil and niacin have
not been systematically associated with depression,
although idiosyncratic depressive reactions are possible;
bile acid sequestrants (eg, cholestyramine) similarly have
low rates of associated neuropsychiatric effects, includ-
ing depression.
94
Summary
In summary, the vast majority of the association between
depression and cardiovascular medications are docu-
mented by case reports and open trials that are unable
to definitively answer questions about causality. Many
cardiovascular agents cause fatigue and sedation (which
may mimic depression) at rates greater than with
placebo, and case reports of medication-induced mood
syndromes exist for many cardiovascular drugs.
Depression has been associated with β-blockers, methyl-
dopa, and reserpine, but more recent syntheses of the
data have suggested that these associations are much
weaker than originally believed, especially when more
comprehensive prospective trials have been performed.
Though low cholesterol has been associated with depres-
sion and suicide, lipid-lowering agents have not been
associated with these adverse effects.
Anti-infective agents
In an infected, medically ill, withdrawn patient, differ-
entiating among illness effects, psychological responses
to illness (eg, demoralization), and medication side
effects (including neuropsychiatric manifestations) can
be difficult. Acutely ill, infected individuals often com-
plain about malaise, dysphoria, fatigue, and insomnia;
together these symptoms can be confused with a clinical
syndrome of depression and be attributed to the most
recent medication added to the regimen (which will
often be an anti-infective agent). In such a scenario,
cytokine-driven sickness behavior can account for much
of the observed psychopathology and subjective mis-
ery
95,96 and will often offer a better explanation than will
medication-induced depression. In addition, in a with-
drawn patient, a hypoactive delirium secondary to an
infection might be mistaken for “depression.”
97
Antibiotic medications
Most antibiotics used to treat infections are well toler-
ated and are unlikely to cause MDD. Nonetheless, iso-
lated case reports (eg, “fluoroquinolone-induced depres-
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toms.
98 Interestingly, some antibiotics have even played
a role in the development of effective, modern antide-
pressants (eg, isoniazid),
99 and some antibiotics (includ-
ing the β-lactam, ceftriaxone) are currently being inves-
tigated as antidepressants due to their effect on
glutamate transmission.
100 Numerous case reports link
anti-infective agents to depression (including antituber-
culous agents [eg, cycloserine, ethionamide], metronida-
zole, or quinolones).
101 Antituberculosis agents (eg, iso-
niazid, cycloserine, and fluoroquinolones) have been
associated (rarely) with seizures and psychosis; these
manifestations, if left unrecognized, could be mistaken
for depression.
102
Antiretroviral medications
Effective treatment for Human Immunodeficiency Virus
(HIV) infection/Acquired Immunodeficiency Syndrome
(AIDS) involves the use of combination antiretroviral
therapies (cART). One commonly used first-line cART
regimen includes the non-nucleoside reverse transcrip-
tase inhibitor (NNRTI), efavirenz. Among the anti-
retroviral agents, efavirenz has been frequently associ-
ated with neuropsychiatric side effects (eg, vivid dreams,
anxiety, depressive symptoms).
103 Such side effects seem
to be transient in most patients
104 and dose-related.
105
Moreover, a polymorphism in the CYP2D6 gene has
been associated with efavirenz plasma concentrations.
106
While genotype-based dose reduction was reported as a
successful strategy in reducing efavirenz-associated CNS
symptoms,
107 the role of pharmacogenetics and thera-
peutic drug monitoring (TDM) for optimal efavirenz
dosing needs further refinement.
Some medications used in the treatment of HIV-infec-
tion/AIDS might mimic depression. The first antiretro-
viral agent to treat HIV infection, zidovudine (AZT), for
example, causes fatigue associated with significant ane-
mia.
108 AZT has also been linked with a variety of CNS
effects (including insomnia, restlessness, and irritability)
that can be mistaken for manifestations of agitated
depression, if the reasonably well established AZT-
induced mania is missed.
109
Interferon-α
IFN-α, in combination with ribavirin, is an effective
treatment for chronic hepatitis C virus (HCV) infection.
IFN-α is the prototype for a chemically-induced bona
fide depressive syndrome; it induces significant depres-
sive symptoms in up to 58% of patients,
110 disrupts sleep
continuity, and increases evening cortisol.
111 The patho-
physiology of interferon-induced depression is likely
related to IFN’s induction of a key enzyme of trypto-
phan catabolism, indoleamine 2,3-dioxygenase (IDO).
112
IDO activation has downstream consequences, includ-
ing an increase in brain kynurenine, which correlates
with depressive symptoms.
112
Depression that emerges during HCV treatment with
IFN-α is a dreaded complication that can lead to early
treatment discontinuation.
113 In one prospective study of
162 patients (who were regularly assessed with a self-rat-
ing depression scale [the Zung Self-Rating Depression
Scale] for the duration of a 24-week treatment trial),
depression at baseline was the best predictor of the
eventual development of moderate to severe depres-
sion.
114 Randomized trials of serotonergic antidepres-
sants for prophylactic treatment of depression have
shown mixed results, with most studies failing to show a
clear benefit.
115,116 However, it is reassuring to know that
patients who develop depression during IFN-based
treatment for HCV respond to initiation of an antide-
pressant agent.
117
Antimalarial medications
Among commonly employed prophylactic malaria reg-
imens, use of mefloquine has most often been consid-
ered as (in prospective, randomized trials) a stimulus for
depression. Van Riemsdijk and colleagues
118 found
higher depression scores and fatigue in patients ran-
domized to prophylactic mefloquine in comparison to
atovaquone plus chloroguanide. A four-arm trial com-
paring mefloquine, atovaquone-proguanil, chloroquine-
proguanil, and doxycycline revealed the highest rate of
neuropsychological manifestations in the mefloquine
arm, particularly among women.
119 A more detailed
analysis found similar mood profiles for all four treat-
ment groups (with the exception of women using meflo-
quine, who showed more fatigue and confusion).
120This
gender-specific vulnerability to side effects is consistent
with a genetic study that examined polymorphisms in
the MDR1/ABCB1 gene (encoding for the efflux pump
P-glycoprotein) and which found an association between
a particular haplotype and neuropsychiatric side effects
of mefloquine that were limited to females.
121 By con-
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trast, one large, observational study was unable to con-
firm an increased risk of depressive symptoms associ-
ated with mefloquine when compared with prophylactic
use of other antimalarials.
122
Antifungal medications
Amphotericin B (used for serious, systemic fungal infec-
tions like cryptococcal meningitis in immunocompro-
mised patients) has been associated with acute CNS tox-
icity, including “delirium and depression.”
123
Summary
In a comprehensive literature review, Patten and Barbui
124
identified only IFN-α and mefloquine as the anti-infec-
tive drugs that had good evidence for being a causative
agent for depressive symptoms. To this list, we would add
the antiretroviral, efavirenz. Patten and Barbui
124 further
concluded that many reports of so-called medication-
induced depressions merely describe isolated, nonspecific
neuropsychiatric symptoms (eg, insomnia, malaise) but
not a full depressive syndrome. Anti-infective agents can
appear “depressogenic” if they are given to a patient with
delirium or if they contribute to the development of delir-
ium. Moreover, both depression and anxiety are com-
monly seen as delirium resolves; such post-delirium mood
states should not be attributed to the medications respon-
sible for the delirium itself.
125
Oncologic medications
The association between cancer and psychiatric disor-
ders has been repeatedly documented; approximately
10% to 25% of cancer patients develop MDD or signif-
icant depressive symptoms.
3As with other medical con-
ditions, the diagnosis of depression in patients with can-
cer is often challenging, since several somatic symptoms
of depression overlap with those of cancer and the side
effects of its treatment.
Many researchers have investigated the incidence of
depression in patients undergoing chemotherapy regi-
mens. Except for a few agents, evidence of chemother-
apy-induced depression is scarce. However, the conclu-
sions are controversial. Further complicating the
assessment is the use of multiple agents in treatment
protocols (often involving corticosteroids) and a lack of
standardized depression measures across studies.
Chemotherapy agents
Alkylating agents
The evidence for the depressogenic effects of alkylating
agents (eg, procarbazine, carmustine, busulfan) is sparse.
Nevertheless, depression is listed as an adverse reaction
to procarbazine in several textbooks and in its product
insert.
126 However, only one report describes the devel-
opment of “depression and lassitude.”
127 Furthermore, no
prospective reports focus directly on the incidence of
MDD with this agent; interestingly, this agent is a weak
MAOI that has been associated with mania and sero-
tonin syndrome. 
Phase II trials of carmustine have reported that depres-
sion occurs in up to 16% of carmustine-treated patients
(compared with 10% of those receiving placebo); how-
ever, this information is derived from questionnaires
about toxicity and not from standardized psychiatric
evaluations.
128 Likewise, depression was reported in 23%
of patients receiving busulfan in clinical trials, when
busulfan was employed as part of the treatment for stem
cell transplant recipients.
129
Vinca alkaloids
In vitro, vinca alkaloids almost completely inhibit the
release of dopamine-β-hyroxylase, thereby interfering
with the conversion of dopamine to norepinephrine
130;
this process has been linked with the development of
irritability and depression in patients receiving vin-
cristine
131 and vinblastine.
132
Antimetabolites
Antimetabolite drugs interact with specific enzymes by
inhibiting the enzyme or causing the synthesis of aber-
rant molecules that cannot function normally.
Pemetrexed, an antifolate antimetabolite, has been
reported to cause mood disturbances (including depres-
sion). One large multicenter phase III trial found
depressive symptoms in 11% of those receiving peme-
trexed.
133Another multicenter study examined a regimen
of pemetrexed and cisplatin and found a 14% rate of
occurrence.
134
Depression has been listed among the adverse reactions
to fludarabine, another antimetabolite; however, this has
not been reported often during controlled trials that
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study examining the safety of oral fludarabine showed a
statistically significant improvement in the mean scores
of emotions among patients who received this agent.
135
Medications that interfere with DNA and RNA synthesis
Doxorubicin and daunorubicin are anthracyclic antibi-
otics that act by binding to DNA and disordering syn-
thesis. Based on animal models, this class of medications
is potentially neurotoxic; however, at therapeutic doses
in humans these agents do not cross the blood-brain bar-
rier. Depression is not commonly associated with these
agents; nevertheless, one prospective, randomized phase
III trial (comparing doxorubicin and daunorubicin for
the treatment of Kaposi’s sarcoma), reported the inci-
dences of depression as 6% and 10%, respectively.
136
L-Asparaginase (a naturally occurring enzyme that
inhibits protein, DNA, and RNA synthesis in tumor cells
by decreasing circulating levels of asparagine) has been
associated with assorted psychiatric symptoms (includ-
ing irritability, depression, and hallucinations). Haskell
and colleagues
137 reported that up to 31% of patients
taking this medication developed CNS abnormalities
(most commonly moderate to severe depression associ-
ated with personality disturbances). Ohnuma
138 reported
that 25% of patients developed mild depression and
drowsiness within 1 month of therapy; higher doses were
related with more severe symptoms, and discontinuation
of it led to the resolution of symptoms.
139
Mitotic inhibitors
Taxane drugs (ie, paclitaxel and docetaxel) are mitotic
inhibitors that interfere with the normal breakdown of
microtubules during cell division. Several studies have
found an association between these medications and
depressive symptoms. One case report of a woman receiv-
ing paclitaxel described the onset of severe depression
and suicidal thoughts that remitted following the discon-
tinuation of the drug.
140 In a prospective RCT, Fountzilas
and associates
141 reported worse emotional function in
those receiving paclitaxel as part of a multidrug regimen
as compared with those receiving the same regimen with-
out paclitaxel. Finally, in a naturalistic, longitudinal study,
Thornton and coworkers
142 documented slower psycho-
logical recovery and higher rates of depressive symptoms
in patients receiving paclitaxel and docetaxel.
Biological agents 
Interleukins
Interleukin-2 (IL-2) has been used in the treatment of
metastatic renal cancer, melanoma, and other malig-
nancies. Early observations reported the development
of clinically significant neuropsychiatric changes during
treatment with IL-2; behavioral and cognitive changes
(including elevated depression scores) appeared to be
dose-related. Walker and coworkers
143 found higher
scores in the Hospital Anxiety and Depression Scale in
patients receiving IL-2 therapy used for advanced col-
orectal cancer (compared with those on standard
chemotherapy). Finally, Capuron and colleagues
144
found elevated depression scores in patients receiving
IL-2, potentially reflecting authentic changes in mood
states rather than somatic symptoms alone. In a later
study, the same authors showed that mood symptoms
correlated with increased serum cytokine levels during
treatment.
145
Corticosteroids
Corticosteroids are used to treat the symptoms of a
number of neurologic (eg, MS), rheumatologic (eg,
rheumatoid arthritis), gastrointestinal (eg, Crohn’s dis-
ease, ulcerative colitis), and respiratory (eg, chronic
obstructive pulmonary disease, asthma) diseases char-
acterized by excessive inflammation. They also are com-
monly indicated in oncologic patients, both to reduce
inflammation around tumors as well as to reduce the
side effects induced by chemotherapy agents. These
agents have been associated with a broad range of neu-
ropsychiatric symptoms, varying from subtle anxi-
ety/depression to full-blown affective and psychotic dis-
orders. Early studies suggested these side effects were
dose-dependent.
146 Depressive disorders are commonly
associated with long-term corticosteroid therapy. One
study found that chronic corticosteroid-treated patients
had significantly greater depressive symptom severity as
well as global psychiatric symptom severity, and a 60%
lifetime risk for mood and anxiety disorders.
147 Breitbart
and associates
148 examined the impact of steroids in can-
cer patients, and found an increased incidence of depres-
sive disorders in patients receiving high-dose dexam-
ethasone for the treatment of spinal cord compression.
The authors noted psychological stress increased as the
Pharmacological aspects
118
PAGES_11_AG_1040_BA.qxd:DCNS#48  5/03/11  11:37  Page 118dosage was tapered, and it was difficult to determine
whether symptoms resulted from dose-reduction of
cumulative steroid exposure. Corticosteroids are thought
to induce mood symptoms by elevating plasma cortisol
concentrations; interestingly, hypothalamic-pituitary-
adrenal axis dysfunction has been strongly associated
with the development of depression in cancer patients. 
Tyrosine kinase inhibitors
Tyrosine kinase inhibitors have potent activity against a
variety of tyrosine kinases, each with specific molecular
targets and mechanisms of action. The prescribing infor-
mation for several of these agents lists depression as an
adverse effect. Early trials of imanitib found depressed
mood to occur in 7% to 15% patients, with more severe
depressive symptoms (with significant dysfunction or
suicidal ideation) occurring in less than 1% of patients.
149
However, a meta-analysis of clinical trials using imatinib
for the treatment of chronic myeloid leukemia did not
report depression among the commonly encountered
side effects.
150 Quek and associates
151 reported seven pre-
viously healthy patients who developed depression
within 6 months of starting treatment with imatinib and
dasatinib; in all cases, symptoms improved after dose
reduction and discontinuation of the drug. In two of
these cases, symptoms reappeared after a drug rechal-
lenge. Similarly, depressed mood is listed as an adverse
reaction in the prescribing information for cetuximab,
dasatinib, sorafenib, and sunitinib; meta-analysis of clin-
ical trials and literature reviews of these agents do not
report any data on the statistically significant occurrence
of depressive symptoms. Finally, using a standardized
tool, Pirl and associates
152 failed to find a statistically sig-
nificant association between depressive symptoms and
concomitant use of gefitinib or erlotinib. 
Hormonal agents
Estrogen and testosterone deficiencies have been linked
to MDD. Presumed mechanisms include alteration of
the concentration and availability of neurotransmitters
amines, including serotonin. Treatment of hormone-sen-
sitive tumors involves use of medications aimed at
reducing availability of sex hormones. Studies evaluat-
ing the association between depression and treatment
with tamoxifen have yielded diverse results. In some tri-
als, a subset of patients have discontinued tamoxifen
therapy because of depressive symptoms, whereas in
other studies, conducted primarily in the breast cancer
prevention setting, no increased risk of depression was
observed during treatment.
153
Similarly, studies on aromatase inhibitors have yielded
mixed results. A large clinical trial involving 9366 post-
menopausal women with localized breast cancer com-
pared anastrozole and tamoxifen; they reported depres-
sive symptoms occurring in 19.3% of patients treated
with anastrozole.
154 However, subsequent studies have
not replicated these findings. Finally, gonadotropin
releasing hormone (GnRH) agonists (ie, leuprolide and
goserelin), have been associated with depression in non-
cancer populations. Clinical trials in prostate cancer
patients have showed diverse results, and well-controlled
prospective studies have suggested that depression
occurs, although fatigue is more prevalent and may be
mistaken for depression.
155
Miscellaneous medications
Isotretinoin
Patients with acne are at an increased risk for depres-
sion, with prevalence rates of up to 30% reported in
patients who suffer from moderate to severe acne.
156 One
of the most effective treatments for nodulocystic acne,
isotretinoin (a synthetic oral retinoid medication),
became a source of significant concern due to its poten-
tial link with the development of depressive symptoms.
Evidence for concerns about depressive symptoms and
suicidal ideation came primarily from case reports and
case series.
157 More recently, however, these claims have
been challenged by the results of both retrospective and
prospective trials. In a systematic review of nine stud-
ies evaluating the psychiatric effects of isotretinoin,
Marqueling and associates
158 found no association
between the use of isotretinoin and depression.
Approximately 1% to 11% of isotretinoin-treated
patients developed depressive symptoms (a rate similar
to that found in patients receiving oral antibiotics).
158
Subsequently, prospective studies have provided further
evidence for lack of an association between isotretinoin
and depression
159,160; only one study has found an
increased risk for depression.
161 However, existing
prospective studies may not be large enough to detect
subtle increases in depression rates; therefore, while
there does not appear to be a significant increase in
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cases of depression may still be attributed to isotretinoin
treatment.
Medications for the treatment of infertility
Infertility, occurring in approximately 10% to 14% of
women, represents a significant life stressor for affected
women.
162 Although the results are mixed, some studies
have shown that depression in infertile women is twice
as high as it is in fertile women.
163 Abnormalities in the
hypothalamic-pituitary-gonadal axis, infertility-associ-
ated stress (with subsequent elevation in stress hormone
levels), and use of medications to treat infertility may all
contribute to depressive symptoms.
162 In a recent review,
Wilkins and associates
162 noted three classes of fertility
medications associated with depression: oral contracep-
tives containing progesterone, gonadotrophin-releasing
hormone agonists (eg, leuprolide), and clomiphene cit-
rate.
162
Oral contraceptive pills (OCPs) and depot contracep-
tives have long been associated with depression.
164
Several factors (eg, a personal history of psychiatric ill-
ness, a family history of OCP-related mood complaints,
and a propensity for hormone-related mood symptoms
[eg, premenstrual or pregnancy-related emotional
changes]) have been considered to increase the risk of
depression.
165 However, more recent data from RCTs
have failed to confirm the association seen in these ear-
lier studies. In a retrospective analysis of 290 patients
with a history of depression, those who were on combi-
nation OCPs or progestin-only contraceptives had less
severe depression, fewer comorbid anxiety disorders,
and better physical function than patients not taking
contraceptives.
166 These findings were confirmed
prospectively by O’Connell and associates,
167 who per-
formed a double-blind, randomized, placebo-controlled
trial of combination OCPs in 76 adolescents (finding
fewer depressive symptoms in patients on OCPs).
Therefore, the results regarding the impact of contra-
ceptive medications on a propensity to depression are
inconclusive.
GnRH agonists (such as leuprolide and goserelin) can
have a number of psychiatric effects. Although these
medications have been used successfully for the treat-
ment of premenstrual syndrome (including feelings of
sadness) in some patients,
168 in other patients these med-
ications have been associated with depression.
169 In the
original studies by the manufacturer, 22% of leuprolide-
treated patients and 54% of goserelin-treated patients
suffered from significant depressive symptoms.
170,171
These findings (for both medications) have been repli-
cated in subsequent case series.
172,173 Furthermore, a ret-
rospective study found that approximately 80% of
patients treated with leuprolide suffered from significant
depressive symptoms (eg, Hamilton Rating Scale for
Depression-21 score ≥20).
174 However, a lack of prospec-
tive studies makes it difficult to identify the risk associ-
ated with these medications. Interestingly, prophylactic
treatment with SSRIs appears to prevent the develop-
ment of depressive symptoms in these patients.
169,174
Clomiphene citrate, a selective estrogen receptor mod-
ulator used to induce ovulation, has been associated with
mood lability and depressed mood in two cross-sectional
studies.
175,176 In the larger of these studies, 67 of 162
(41%) of clomiphene-treated women experienced
depressed mood and 75 of 162 (45%) experienced mood
swings during treatment.
176 Unfortunately, there are no
prospective studies that evaluate the association
between clomiphene and psychiatric symptoms; never-
theless, given the evidence from cross-sectional studies,
care should be taken when prescribing this medication
to infertile women.
In sum, there is mixed evidence regarding the depresso-
genic effects of medications for the treatment of infer-
tility. Although progesterone-containing contraceptives
caused the most concern through case reports and ret-
rospective studies, systematic prospective studies have
revealed that these medications are rarely linked to
depressive symptoms. Preliminary cross-sectional and
retrospective studies also suggest a possible link between
depression and the use of GnRH agonists and
clomiphene citrate; however, prospective studies will be
required to confirm these associations. 
Varenicline
Varenicline, a nicotinic receptor partial agonist, is used
clinically to facilitate smoking cessation. Since its intro-
duction, it has been scrutinized as several case reports and
retrospective studies have noted worsening mood and sui-
cidal ideation during its use
177,178; these findings have led to
a Food and Drug Administration warning about vareni-
cline.
179 However, large observational cohort studies have
failed to confirm an increase in depression or suicidal
risk
180,181; further, an open-label study found a significant
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varenicline.
182The finding that smoking cessation itself can
precipitate depressive symptoms in patients with nicotine
dependence may partly explain the early case reports
linking varenicline and depression.
183 Therefore, while
idiosyncratic depressive reactions are possible during
treatment with varenicline, there is no clear evidence that
this medication is depressogenic. Further studies should
be performed to further clarify these findings.
Conclusions
The medical literature is replete with reports of depres-
sion caused by a certain pharmacologic agent. As noted,
these reports are often compromised by small or biased
samples, lack of standardized depression assessments,
and by the high prevalence of depression in the med-
ically ill. Often, when prospective studies are performed,
these agents do not in fact appear to cause depression in
most patients, and their use should not be avoided in
patients at risk for depression, especially if they are
important for the treatment of the underlying medical
condition. Unfortunately, few prospective studies—espe-
cially challenge-dechallenge-rechallenge trials—have
been performed to evaluate the psychiatric effects of
medications purported to cause depression. The lack of
confirmation by prospective studies highlights the
importance of the systematic evaluation of psychiatric
side effects of medications, as basing clinical practice on
case reports often can lead to withholding beneficial
treatments for fear of rare side effects.
However, some agents appear to cause depression in a
minority of patients. These agents include barbiturates,
vigabatrin, topiramate, flunarizine, corticosteroids, meflo-
quine, efavirenz, and IFN-α. These agents should be
used more cautiously in patients with current or prior
depression, or those who are otherwise at high-risk for
depression. Depression is rarely an absolute contraindi-
cation to the use of a medication, but several factors
should be weighed by clinicians to make the best pre-
scribing decision for a given patient. These factors
include the extent of potential benefit of the medication
on the medical condition, the existence of nondepresso-
genic alternative medications to treat the condition, the
patient’s history of depression (and severity of prior
depressive episodes), and the ability to monitor the
patient for depression. 
Finally, one final clinical caveat: though a certain med-
ication may not cause a depressive syndrome in the gen-
eral population, idiosyncratic reactions can occur as the
result of genetic vulnerabilities and environmental stres-
sors (eg, concurrent medications). Therefore, if a patient
develops depressive symptoms after the initiation of a
given agent (especially after an ‘on-off-on’ trial suggest-
ing consistent onset of depression with the medication),
another agent should be strongly considered.  ❏
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Efectos depresógenos de los medicamentos:
una revisión
La literatura está llena de reportes que relacionan
los medicamentos con el inicio o la progresión de
la depresión. Dado que la depresión es tan fre-
cuente en pacientes con enfermedad médica,
puede ser desafiante el evaluar si un medicamento
de hecho ha causado la depresión o si la relación
es sólo una coincidencia. En este artículo se revisa
la literatura relacionada con la asociación entre
medicamentos y depresión. Para la mayoría de los
fármacos hay reportes de casos o pequeños estu-
dios que vinculan la medicación con el inicio de la
depresión, pero estudios prospectivos más riguro-
sos no existen o no encuentran asociación entre el
fármaco y la depresión. Sin embargo, varios medi-
camentos (por ejemplo, barbitúricos, vigabatrina,
topiramato, flunarizina, corticoides, mefloquina,
efavirenz e interferon-alfa) parecen causar depre-
sión en algunos pacientes y deben utilizarse con
cautela en pacientes con riesgo de depresión.  
Une analyse des effets dépressogènes des
médicaments
La littérature regorge de rapports qui relient les
médicaments à la survenue ou à la progression
d’une dépression. La dépression étant très courante
chez les personnes malades, l'évaluation de l’impli-
cation du médicament dans l’installation de la
dépression, ou de la coïncidence de la relation
observée, peut s'avérer difficile. Dans cet article,
nous effectuons une revue des liens entre médica-
ments et dépression. Pour la plupart des produits,
des rapports de cas ou de petites études associent
le médicament à la survenue de la dépression, mais
il manque des études prospectives plus rigoureuses
ou celles qui existent n’ont pas trouvé de lien entre
le produit et la dépression. Cependant, plusieurs
médicaments (barbituriques, vigabatrine, topira-
mate, flunarazine, corticoïdes, méfloquine, éfavi-
renz et interféron-) semblent provoquer une
dépression chez certains patients et doivent être
utilisés avec précaution chez les patients ayant un
risque de dépression.
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